Last edition
News about "ovarian cancer therapy"
Gilead Expands Oncology Pipeline with Tubulis Acquisition
Gilead to acquire Tubulis, adding TUB-040 ADC for ovarian cancer and a next-generation platform with Tubutecan technology, strengthening its oncology pipeline and ADC capabilities.
Ovarian Cancer Therapy | 08/04/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members